IL1B and COVID-19: Moreover, the anti-inflammatory properties of Febuxostat, through inhibition of the JAK/STAT and NF-κB pathways and subsequent reduction in pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, may underlie its protective effects against COVID-19-related hyperinflammation and organ damage (Hao et al., 2019; Khan et al., 2017; Abo-Youssef et al., 2020).